Tesamorelin is a lab-made version of growth hormone-releasing factor, the brain hormone that prompts the pituitary gland to release growth hormone.1 It is FDA-approved as Egrifta for one use: reducing excess abdominal fat in adults with HIV and lipodystrophy. Drugs@FDA lists its original approval on November 10, 2010.1,2 The label states that it is not indicated for weight loss and that its long-term cardiovascular safety has not been established.1 The approval rests on two randomized, placebo-controlled trials of about 400 adults each, in which visceral abdominal fat fell more with tesamorelin than with placebo.1
Tesamorelin at a glance
What it is
A growth hormone-releasing factor (GHRF) analogue. The label states that it binds to and stimulates human GRF receptors with potency similar to the natural hormone.1
FDA status
FDA-approved. Drugs@FDA lists Egrifta (first approved November 10, 2010), and the label covers reducing excess abdominal fat in adults with HIV and lipodystrophy. The cited label has no boxed warning.1,2
Human evidence
Two large randomized, double-blind, placebo-controlled trials described in the label, each with a 26-week main phase and a 26-week extension.1
Evidence strength
Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned
What is tesamorelin?
Tesamorelin is a lab-made analogue of growth hormone-releasing factor (GHRF), also called growth hormone-releasing hormone (GHRH). The label describes GHRF as a hypothalamic peptide that acts on the pituitary gland to stimulate the release of the body’s own growth hormone.1
In the United States it is the active ingredient of Egrifta, from Theratechnologies, according to Drugs@FDA.2
How does tesamorelin work?
The label states that tesamorelin binds to and stimulates human GRF receptors with potency similar to the natural hormone, prompting the pituitary to make and release growth hormone.1
According to the label, growth hormone has both tissue-building and fat-breaking effects, some of which are carried by IGF-1, a growth factor made in the liver and other tissues.1
The label states that tesamorelin increases IGF-1 levels and that the effects of prolonged IGF-1 elevation are unknown.1
What do human studies show?
The label describes two randomized, double-blind, placebo-controlled trials in adults with HIV, lipodystrophy and excess abdominal fat who were on stable HIV treatment: Study 1 with 412 participants and Study 2 with 404.1
At 26 weeks, visceral abdominal fat measured by CT scan fell by an average of 18% with tesamorelin and rose 2% with placebo in Study 1, and fell 14% with tesamorelin and 2% with placebo in Study 2, according to the label.1
Body weight barely changed in either group, consistent with the label’s statement that the drug is not indicated for weight loss because it has a weight-neutral effect.1
The label reports 26-week completion rates of 80% in Study 1 and 74% in Study 2. The trials excluded people with a history of cancer, an underactive pituitary gland, or previous treatment with insulin or other diabetes medicines.1
What the evidence base contains
Large randomized human trial Study 1 (NCT00123253): a randomized, double-blind, placebo-controlled trial in 412 adults with HIV, lipodystrophy and excess abdominal fat, with visceral fat measured by CT scan at 26 weeks.1
Large randomized human trial Study 2 (NCT00435136): a randomized, double-blind, placebo-controlled trial of the same design in 404 adults.1
Yes. Drugs@FDA lists Egrifta, application BLA022505, with an original approval date of November 10, 2010.2
The Egrifta SV label cited here (DailyMed SPL version 9, published July 31, 2026) states that it is indicated for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.1
The label lists these limitations of use: long-term cardiovascular safety has not been established, it is not indicated for weight loss, and there are no data showing that it improves adherence to HIV treatment.1
The label has no boxed warning. It states that tesamorelin is contraindicated in pregnancy, in people with active cancer, with disruption of the hypothalamic-pituitary axis, or with known allergy to it.1
Its warnings cover an increased risk of tumors, elevated IGF-1, fluid retention, glucose intolerance or diabetes, allergic reactions and increased deaths in people with acute critical illness.1
DailyMed publishes the Egrifta SV label version cited on this page.1
What is still unknown?
Its long-term cardiovascular safety, which the label says has not been established.1
The effects of keeping IGF-1 levels raised for long periods, which the label says are unknown.1
Whether the reduction in abdominal fat leads to longer-term health benefits: the label’s trials measured fat by CT scan over 26-week phases.1
Its effects outside the approved population: the label’s trials enrolled adults with HIV and lipodystrophy only.1
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Tesamorelin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Tesamorelin are the records PeptideScanner has selected and published, not every registration or paper about Tesamorelin. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
FDA-approved as Egrifta for HIV-associated abdominal fat. Two randomized, placebo-controlled trials described in the label found larger reductions in visceral abdominal fat than placebo. The label states that it is not indicated for weight loss and that long-term cardiovascular safety has not been established.↗↗
Review source snapshots checked August 19, 2026 · Integrity checked August 19, 2026.
A bounded review of two randomized placebo-controlled trials in adults living with HIV and abdominal fat accumulation.↗↗
What the reviewed sources report
The reviewed trials reported reductions in visceral adipose tissue, and the smaller trial also reported a modest reduction in liver fat. These studies do not establish long-term clinical outcomes or effects outside the studied HIV populations.↗↗
What remains unresolved?
Do the imaging changes translate into durable clinical benefits, and what are the longer-term effects in the studied population?↗↗
The label covers reduction of excess abdominal fat in adults with HIV and lipodystrophy. It explicitly excludes weight-loss management and says long-term cardiovascular safety has not been established. Label: 1 ↗
Which safety limits matter?
Contraindications include disruption of the hypothalamic-pituitary axis, active malignancy, hypersensitivity and pregnancy. Warnings address neoplasms, elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity and acute critical illness. The label says effects of prolonged IGF-1 elevation are unknown. Label: 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Label ZIP SHA-256: 2208a57e39a937407fe40c3d00ff1f8547a7a33e87685d40205cfaba9137cc6c. Extracted XML SHA-256: 280dc13506741337de1fe23ec2d53b3c65241abd9501425611ff106932ca714d.
A bounded review of two randomized placebo-controlled trials in adults living with HIV and abdominal fat accumulation.12
Bottom line from this bounded source set
The reviewed trials reported reductions in visceral adipose tissue, and the smaller trial also reported a modest reduction in liver fat. These studies do not establish long-term clinical outcomes or effects outside the studied HIV populations.12
Reviewed study record
Twenty-six-week visceral-fat trial
Design
A randomized, placebo-controlled trial assessed computed-tomography visceral adipose tissue and metabolic measures over 26 weeks.1
Population
The trial randomized 412 adults living with HIV who had abdominal fat accumulation during antiretroviral therapy; 86% were men.1
Outcomes reported
Visceral adipose tissue reportedly decreased by 15.2% with tesamorelin and increased by 5.0% with placebo. More participants receiving tesamorelin withdrew because of an adverse event, while the groups did not differ significantly in the reported glycemic measures.1
Limitations
The 26-week trial was limited to adults living with HIV and treatment-associated abdominal fat accumulation and did not establish longer-term clinical outcomes.1
Reviewed study record
Six-month visceral- and liver-fat trial
Design
A double-blind, randomized, placebo-controlled preliminary trial assessed visceral adipose tissue, liver fat, and metabolic measures over six months.2
Population
The single-center trial enrolled 50 antiretroviral-treated adults living with HIV and abdominal fat accumulation; 48 received study treatment.2
Outcomes reported
The reported treatment difference was -42 square centimeters for visceral adipose tissue and -2.9 percentage points for liver fat. The six-month glucose changes were not statistically significant.2
Limitations
The preliminary study was small, single-center, and six months long; the authors stated that further study was needed to determine clinical importance and long-term consequences.2
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa072375. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1001/jama.2014.8334. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
FDA’s 2010 assessment describes two 26-week randomized, placebo-controlled trials in HIV-associated lipodystrophy. Their primary endpoint was CT-measured visceral abdominal fat, not cardiovascular events or survival. FDA PDF pp. 3, 7 ↗
More findings, study links and document coverage
Fat reduction did not establish cardiovascular benefit
The review explicitly separates reduced visceral fat from demonstrated cardiovascular benefit. Lipid and body-image results were inconsistent across the two trials, and the body-image instrument had validity concerns. FDA PDF pp. 3, 8, 9 ↗
The extension shows a limit to persistence
Participants switched from tesamorelin to placebo accumulated visceral fat again toward baseline during follow-up. The extension’s switching and selection rules mean it should not be counted as an independent replication of the original trials. FDA PDF pp. 7, 8 ↗
Safety interpretation requires the studied population
The review identifies glucose intolerance, elevated IGF-1 and hypersensitivity concerns. Patients receiving drug treatment for type 2 diabetes were excluded, limiting extrapolation to that broader population. This is a historical assessment, not the current formulation label. FDA PDF pp. 10, 11, 12 ↗
Selected sections read in 1 of 5 inventoried documents; 4 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
Selected English EMA PDFs from the retained September 15, 2026 title-matched document feed, plus independently retrieved FDA approval-package documents where listed. Candidate entries are not verified product/application matches. This is a bounded inventory, not a complete FDA, national or worldwide source search. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
Independently retrieved FDA approval-package PDF. The displayed date belongs to the selected review, not the entire compilation or a current label.
Verified: Egrifta · NDA 022505 · Document dated 2010-11-05. Identity checked on PDF pp. 2.
Identity and selected clinical design, efficacy, safety and benefit-risk sections only. One-based PDF file pages; unlisted pages have not been appraised. The date identifies the selected review within any compiled approval package.
Retrieved 2026-09-19. Read PDF pages: 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12 of 20. SHA-256: 1ba0756ca76e7a8f365d85b1b58c53acf934862ee6f314addda0082f92f88dc1.
European medicine records · 1 products or applications
EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.
Active substance as listed: tesamorelin. EMA record ↗
Application withdrawal: 2012-06-21. EMA metadata last updated 2012-07-18. EMA metadata ↗
Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
104 retrieved · 2 included · 0 excluded · 102 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Tesamorelin"[Title/Abstract] OR "TH9507"[Title/Abstract] OR "Egrifta"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
Showing 25 of 104 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 25038357 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01263717.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 18057338 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT00123253.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 42538058 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42419889 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42395176 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42382101 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42160466 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42139091 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42123471 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42018810 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41966639 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41598480 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41545261 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41490200 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41476424 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41138283 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 40510111 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 40397552 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 39813152 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 39746672 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 38905488 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 38416754 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 38197510 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 37806509 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 36845310 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
FDA BLA022505 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TESAMORELIN ACETATE.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EMEA/H/C/002427 — include: EMA feed product Egrifta; reported status: Application withdrawn. Exact indication and decision documents remain unappraised.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
5 retrieved · 0 included · 0 excluded · 5 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 5 of 5 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 13891 — not screened: Title-name match awaiting identity and document review. Questions and answers on the withdrawal of the marketing authorisation application for Egrifta (tesamorelin)
EMA 32433 — not screened: Title-name match awaiting identity and document review. Ferrer Internacional, S.A. withdraws its marketing authorisation application for Egrifta (tesamorelin)
EMA 32484 — not screened: Title-name match awaiting identity and document review. Withdrawal assessment report for Egrifta
EMA 7574 — not screened: Title-name match awaiting identity and document review. Withdrawal letter: Egrifta (tesamorelin)
EMA 37720 — not screened: Title-name match awaiting identity and document review. P/23/2011: EMA decision of 25 January 2011 on the granting of a product specific waiver for tesamorelin (EMEA-001029-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Counci...
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
25 retrieved · 0 included · 0 excluded · 25 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 25 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT01579695 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00850564 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07481734 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02012556 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02572323 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00123253 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00608023 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01788462 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01632592 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06554717 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05383456 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03150511 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02553603 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02931474 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00795210 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01264497 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03826160 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01388920 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00257712 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00675506 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03226821 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01263717 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02196831 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01591902 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03375788 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Tesamorelin?
FDA-approved as Egrifta for HIV-associated abdominal fat. Two randomized, placebo-controlled trials described in the label found larger reductions in visceral abdominal fat than placebo. The label states that it is not indicated for weight loss and that long-term cardiovascular safety has not been established.↗↗
The cited status sources were checked through August 14, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Bibliography fields unavailable here for 20 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
1
FDA Federal Register documents
3
DailyMed SPL versions
9
Canonical profile
Published
Profile structured data
Published
Linked dated records
45
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsTrial–publication links · 4
These links come only from structured NCT and PMID identifiers declared by PubMed or ClinicalTrials.gov. They do not summarize the publications or establish findings.
ClinicalTrials.gov posted a newer version of NCT03150511, with a registry update date of 2026-11-09. This version reports that observation; the earlier retained observation remains available as version 1.
ClinicalTrials.gov posted a newer version of NCT07481734, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
Selected records span January 19, 2010 to November 12, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin.↗
PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was tesamorelin.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41545261 at 2026-08-10T10:49:08.747Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-01-16. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
DailyMed lists Structured Product Labeling version 9 for the reviewed Tesamorelin label family with a published date of 2026-07-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42419889 at 2026-08-10T10:49:10.753Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-08. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 22495074 at 2026-08-10T18:13:32.273Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2012-04-13. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained ClinicalTrials.gov record NCT06554717 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was tesamorelin.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 34006921 at 2026-07-30T16:22:11.959Z. PubMed recorded a metadata revision date of 2026-04-07 and an Entrez history date of 2021-05-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38905488 at 2026-07-30T16:22:12.148Z. PubMed recorded a metadata revision date of 2026-04-01 and an Entrez history date of 2024-06-21. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained ClinicalTrials.gov record NCT02572323 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tesamorelin.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 17571443 at 2026-07-30T16:30:45.652Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2007-06-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 21115997 at 2026-07-30T16:30:48.398Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2010-12-01. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗